These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 24015967)

  • 1. Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains.
    Mirguet O; Gosmini R; Toum J; Clément CA; Barnathan M; Brusq JM; Mordaunt JE; Grimes RM; Crowe M; Pineau O; Ajakane M; Daugan A; Jeffrey P; Cutler L; Haynes AC; Smithers NN; Chung CW; Bamborough P; Uings IJ; Lewis A; Witherington J; Parr N; Prinjha RK; Nicodème E
    J Med Chem; 2013 Oct; 56(19):7501-15. PubMed ID: 24015967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The making of I-BET762, a BET bromodomain inhibitor now in clinical development.
    Zhao Y; Yang CY; Wang S
    J Med Chem; 2013 Oct; 56(19):7498-500. PubMed ID: 24107192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Activity Relationship Study of N(6)-Benzoyladenine-Type BRD4 Inhibitors and Their Effects on Cell Differentiation and TNF-α Production.
    Amemiya S; Yamaguchi T; Sakai T; Hashimoto Y; Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(9):1378-83. PubMed ID: 27581642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small-Molecule Targeting of BET Proteins in Cancer.
    French CA
    Adv Cancer Res; 2016; 131():21-58. PubMed ID: 27451123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.
    Gosmini R; Nguyen VL; Toum J; Simon C; Brusq JM; Krysa G; Mirguet O; Riou-Eymard AM; Boursier EV; Trottet L; Bamborough P; Clark H; Chung CW; Cutler L; Demont EH; Kaur R; Lewis AJ; Schilling MB; Soden PE; Taylor S; Walker AL; Walker MD; Prinjha RK; Nicodème E
    J Med Chem; 2014 Oct; 57(19):8111-31. PubMed ID: 25249180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and characterization of small molecule inhibitors of the BET family bromodomains.
    Chung CW; Coste H; White JH; Mirguet O; Wilde J; Gosmini RL; Delves C; Magny SM; Woodward R; Hughes SA; Boursier EV; Flynn H; Bouillot AM; Bamborough P; Brusq JM; Gellibert FJ; Jones EJ; Riou AM; Homes P; Martin SL; Uings IJ; Toum J; Clement CA; Boullay AB; Grimley RL; Blandel FM; Prinjha RK; Lee K; Kirilovsky J; Nicodeme E
    J Med Chem; 2011 Jun; 54(11):3827-38. PubMed ID: 21568322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bromodomains: Structure, function and pharmacology of inhibition.
    Ferri E; Petosa C; McKenna CE
    Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
    Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
    J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
    Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
    Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.
    Morse MA; Balogh KK; Brendle SA; Campbell CA; Chen MX; Furze RC; Harada IL; Holyer ID; Kumar U; Lee K; Prinjha RK; Rüdiger M; Seal JT; Taylor S; Witherington J; Christensen ND
    Antiviral Res; 2018 Jun; 154():158-165. PubMed ID: 29653131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains.
    Picaud S; Da Costa D; Thanasopoulou A; Filippakopoulos P; Fish PV; Philpott M; Fedorov O; Brennan P; Bunnage ME; Owen DR; Bradner JE; Taniere P; O'Sullivan B; Müller S; Schwaller J; Stankovic T; Knapp S
    Cancer Res; 2013 Jun; 73(11):3336-46. PubMed ID: 23576556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of Benzo[
    Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
    J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
    Fish PV; Filippakopoulos P; Bish G; Brennan PE; Bunnage ME; Cook AS; Federov O; Gerstenberger BS; Jones H; Knapp S; Marsden B; Nocka K; Owen DR; Philpott M; Picaud S; Primiano MJ; Ralph MJ; Sciammetta N; Trzupek JD
    J Med Chem; 2012 Nov; 55(22):9831-7. PubMed ID: 23095041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine.
    Kharenko OA; Patel RG; Brown SD; Calosing C; White A; Lakshminarasimhan D; Suto RK; Duffy BC; Kitchen DB; McLure KG; Hansen HC; van der Horst EH; Young PR
    J Med Chem; 2018 Sep; 61(18):8202-8211. PubMed ID: 30165024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of BET bromodomains.
    Filippakopoulos P; Qi J; Picaud S; Shen Y; Smith WB; Fedorov O; Morse EM; Keates T; Hickman TT; Felletar I; Philpott M; Munro S; McKeown MR; Wang Y; Christie AL; West N; Cameron MJ; Schwartz B; Heightman TD; La Thangue N; French CA; Wiest O; Kung AL; Knapp S; Bradner JE
    Nature; 2010 Dec; 468(7327):1067-73. PubMed ID: 20871596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding Assays for Bromodomain Proteins: Their Utility in Drug Discovery in Oncology and Inflammatory Disease.
    Zolotarjova NI; Wynn R
    Curr Protoc Pharmacol; 2018 Mar; 80(1):3.16.1-3.16.14. PubMed ID: 30040205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel [1,2,4]triazolo[4,3-a]quinoxaline aminophenyl derivatives as BET inhibitors for cancer treatment.
    Ali I; Lee J; Go A; Choi G; Lee K
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4606-4613. PubMed ID: 28939121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bromodomains: a new target class for drug development.
    Cochran AG; Conery AR; Sims RJ
    Nat Rev Drug Discov; 2019 Aug; 18(8):609-628. PubMed ID: 31273347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
    Wellaway CR; Bamborough P; Bernard SG; Chung CW; Craggs PD; Cutler L; Demont EH; Evans JP; Gordon L; Karamshi B; Lewis AJ; Lindon MJ; Mitchell DJ; Rioja I; Soden PE; Taylor S; Watson RJ; Willis R; Woolven JM; Wyspiańska BS; Kerr WJ; Prinjha RK
    J Med Chem; 2020 Sep; 63(17):9020-9044. PubMed ID: 32787145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.